Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients
作者: Xiaoyan (Shawn) LiSteve DeitelzweigAllison KeshishianMelissa HamiltonRuslan HorblyukKiran GuptaXuemei LuoJack MardekianKeith FriendAnagha NadkarniXianying PanGregory Y. H. Lip
作者单位: 1Xiaoyan Li, Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA, Tel.: +1 609 302 4478, Email: shawn.li@bms.com
刊名: Thromb Haemost, 2017, Vol.117 (6), pp.1072-1082
来源数据库: Schattauer GmbH
DOI: 10.1160/TH17-01-0068
关键词: Apixabanwarfarinnon-valvular atrial fibrillationstrokemajor bleeding
原始语种摘要: The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, 2015. After 1:1 warfarin-apixaban propensity score matching (PSM) within each database, the resulting patient records were pooled. Kaplan-Meier curves and Cox proportional hazards models were used to estimate the cumulative incidence and hazard ratios (HRs) of stroke/SE and major bleeding (identified using the first listed diagnosis of inpatient claims) within one year of therapy initiation. The study...
全文获取路径: Schattauer 出版社 
影响因子:6.094 (2012)

  • warfarin 杀鼠灵
  • fibrillation 原纤维化
  • atrial 围鳃的
  • valvular 壳瓣的
  • matched 匹配的
  • stroke 笔划
  • propensity 晶癖
  • bleeding 模糊不清
  • initiation 创始
  • major 知的